Two Sigma Investments LP Grows Holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Two Sigma Investments LP increased its stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 222.1% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,012,640 shares of the biopharmaceutical company's stock after acquiring an additional 698,296 shares during the quarter. Two Sigma Investments LP owned approximately 0.49% of Sangamo Therapeutics worth $1,033,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its position in shares of Sangamo Therapeutics by 679.5% in the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 21,793 shares during the period. SBI Securities Co. Ltd. acquired a new stake in Sangamo Therapeutics in the 4th quarter worth about $28,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Sangamo Therapeutics during the 4th quarter worth approximately $353,000. Geode Capital Management LLC raised its holdings in shares of Sangamo Therapeutics by 3.4% during the fourth quarter. Geode Capital Management LLC now owns 2,211,849 shares of the biopharmaceutical company's stock valued at $2,257,000 after acquiring an additional 73,540 shares during the last quarter. Finally, Lazard Asset Management LLC acquired a new position in shares of Sangamo Therapeutics during the fourth quarter valued at approximately $47,000. Hedge funds and other institutional investors own 56.93% of the company's stock.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ SGMO traded down $0.02 during midday trading on Monday, reaching $0.51. 6,077,110 shares of the stock were exchanged, compared to its average volume of 8,853,179. The stock has a market capitalization of $118.92 million, a P/E ratio of -0.68 and a beta of 1.19. The company has a 50 day simple moving average of $0.62 and a 200 day simple moving average of $1.13. Sangamo Therapeutics, Inc. has a twelve month low of $0.30 and a twelve month high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The business had revenue of $6.44 million during the quarter, compared to analysts' expectations of $7.90 million. On average, research analysts expect that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on SGMO shares. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Monday, April 7th. Barclays reduced their target price on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating for the company in a research report on Wednesday, May 14th. Wall Street Zen lowered shares of Sangamo Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, May 30th. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and set a $2.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $4.50.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.